Leukemia

Papers
(The H4-Index of Leukemia is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms1738
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms1487
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis180
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey169
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments150
Molecular biology of Hodgkin lymphoma132
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies125
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma116
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia116
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms106
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leuk105
Catch me if you can: how AML and its niche escape immunotherapy99
Therapeutic implications of menin inhibition in acute leukemias90
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia89
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia85
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 984
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In80
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML79
NK-/T-cell lymphomas72
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial71
The WHO Classification of Haematolymphoid Tumours70
Base-edited CAR T cells for combinational therapy against T cell malignancies70
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia68
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma67
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape67
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib66
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study64
Treatment resistance in diffuse large B-cell lymphoma63
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views63
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival61
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges61
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial61
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)60
Current challenges and unmet medical needs in myelodysplastic syndromes59
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis59
An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner59
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA57
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial56
Decrease post-transplant relapse using donor-derived expanded NK-cells55
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease55
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion55
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML55
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial55
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL55
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations54
Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations53
The KMT2A recombinome of acute leukemias in 202353
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia51
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions51
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b51
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis51
0.10491299629211